These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 34344384)

  • 1. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
    Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
    Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
    Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fertility-sparing re-treatment for endometrial cancer and atypical endometrial hyperplasia patients with progestin-resistance: a retrospective analysis of 61 cases.
    Chen J; Cao D
    World J Surg Oncol; 2024 Jun; 22(1):169. PubMed ID: 38918837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
    Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
    Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.
    Zhou R; Yang Y; Lu Q; Wang J; Miao Y; Wang S; Wang Z; Zhao C; Wei L
    Gynecol Oncol; 2015 Dec; 139(3):424-8. PubMed ID: 26428941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
    Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of pregnancy outcome after fertility-preserving treatment among women with atypical endometrial hyperplasia or endometrial carcinoma].
    Xiao ZR; Lu Q; Zhou R; Wang YQ; Liang WY; Liu HX; Tang HR; Wu GZ; Liu XS; Zhang H; Ren Y; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2020 Dec; 55(12):857-864. PubMed ID: 33355761
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and pregnancy outcomes of hysteroscopic surgery combined with progestin as fertility-sparing therapy in patients with early stage endometrial cancer and atypical hyperplasia.
    Xi Y; Liu G; Liu D; Jiang J; Gong R
    Arch Gynecol Obstet; 2023 Feb; 307(2):583-590. PubMed ID: 35674831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fertility preserving management of early endometrial cancer in a patient cohort at the department of women's health at the university of Tuebingen.
    Andress J; Pasternak J; Walter C; Kommoss S; Krämer B; Hartkopf A; Brucker SY; Schönfisch B; Steinmacher S
    Arch Gynecol Obstet; 2021 Jul; 304(1):215-221. PubMed ID: 33606091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential.
    Pronin SM; Novikova OV; Andreeva JY; Novikova EG
    Int J Gynecol Cancer; 2015 Jul; 25(6):1010-4. PubMed ID: 25950126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
    Gong Q; Chen X; Xie X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continued medical treatment for persistent early endometrial cancer in young women.
    Cho A; Lee SW; Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT
    Gynecol Oncol; 2021 Feb; 160(2):413-417. PubMed ID: 33246662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer.
    Chae SH; Shim SH; Lee SJ; Lee JY; Kim SN; Kang SB
    Int J Gynecol Cancer; 2019 Jan; 29(1):77-85. PubMed ID: 30640687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factors for Recurrence in Patients with Atypical Endometrial Hyperplasia and Endometrioid Adenocarcinoma after Fertility-Sparing Treatments.
    Yin J; Ma S; Shan Y; Wang Y; Li Y; Jin Y; Pan L
    Cancer Prev Res (Phila); 2020 Apr; 13(4):403-410. PubMed ID: 32015095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of prolonged progestin treatment and factors predicting successful fertility-sparing treatment for early endometrial endometrioid adenocarcinoma.
    Ou YC; Fu HC; Lan J; Wu CH; Kung FT; Lan KC; Tsai YC; Lin H
    Eur J Obstet Gynecol Reprod Biol; 2021 Dec; 267():99-104. PubMed ID: 34739876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fertility-sparing treatment of endometrial cancer precursors among young women: a reproductive point of view.
    Ricciardi E; Maniglio P; Frega A; Marci R; Caserta D; Moscarini M
    Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1934-7. PubMed ID: 23242719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia.
    Inoue O; Hamatani T; Susumu N; Yamagami W; Ogawa S; Takemoto T; Hirasawa A; Banno K; Kuji N; Tanaka M; Aoki D
    Reprod Biol Endocrinol; 2016 Jan; 14():2. PubMed ID: 26769300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer.
    Gonthier C; Walker F; Luton D; Yazbeck C; Madelenat P; Koskas M
    Gynecol Oncol; 2014 Apr; 133(1):33-7. PubMed ID: 24680589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of prognosis and pregnancy outcomes of fertility-preserving treatment for patients with stage Ⅰa, grade 2 endometrial cancer].
    Wang YQ; Zhou R; Xu LJ; Xia M; Lu Q; Liu GL; Shen DH; Wang G; He M; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2020 May; 55(5):327-332. PubMed ID: 32464721
    [No Abstract]   [Full Text] [Related]  

  • 20. [The long-term efficacy of metformin in megestrol acetate-based fertility-sparing treatment for patients with endometrial atypical hyperplasia and endometrioid endometrial cancer].
    Dong YT; Guan J; Yang BY; Yierfulati G; Xue Y; Chen XJ
    Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(10):729-735. PubMed ID: 38462352
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.